Literature DB >> 21284709

Japan lags behind the UK in neurological drug approvals.

Rumiko Shimazawa, Masayuki Ikeda.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21284709      PMCID： PMC3045559          DOI： 10.1111/j.1365-2125.2010.03848.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.

Authors:  K Tsuji; K Tsutani
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

2.  Delays in new drug applications in Japan and industrial R&D strategies.

Authors:  Y Hirai; H Kinoshita; M Kusama; K Yasuda; Y Sugiyama; S Ono
Journal:  Clin Pharmacol Ther       Date:  2009-11-25       Impact factor: 6.875
  2 in total
  2 in total

1.  Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?

Authors:  Rumiko Shimazawa; Masayuki Ikeda
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

2.  Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.

Authors:  Mototsugu Tanaka; Mayumi Idei; Hiroshi Sakaguchi; Ryosuke Kato; Daisuke Sato; Kenji Sawanobori; Shuichi Kawarasaki; Toshiyuki Hata; Asako Yoshizaki; Miki Nakamura; Mutsuhiro Ikuma
Journal:  Clin Pharmacol Ther       Date:  2020-11-15       Impact factor: 6.875
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.